ENCINITAS, Calif. and WROCLAW, Poland, Feb. 12, 2026 /PRNewswire/ — Vasa Therapeutics (“Vasa”), a clinical stage biotechnology company developing novel therapies for cardiovascular and metabolic aging, today announced its participation at the 36th Annual Oppenheimer Life Sciences Conference, taking place February 25-26, 2026.
Artur Plonowski, MD, CEO and Co-Founder of Vasa, and Noreen Henig, MD, Chief Medical Officer of Vasa, will present virtually on February 26th, 2026 at 10:40am-11:10am ET. Company management will also meet with investors in one-on-one meetings during the conference.
About Vasa Therapeutics
Vasa Therapeutics is a clinical-stage biopharmaceutical company committed to delivering first-in-class innovation for cardiovascular, neuromuscular and age-related disorders. By focusing on mechanisms with strong clinical relevance, Vasa aims to deliver disease-modifying therapies that drive real patient impact through clinically meaningful and durable outcomes for patients. By pairing the right mechanism with the right chemistry, and with its proprietary know-how and expertise, Vasa is leading the way to create new standards of care.
Vasa has engineered a pipeline of four differentiated assets targeting unmet medical needs in heart failure, peripheral arterial disease, neuromuscular disorders, sarcopenia and life-threatening arrhythmias.
The company is headquartered in Encinitas, CA. For more information, please visit www.vasatherapeutics.com.
Investor and Media Contact:
Mike Geremia
Chief Financial Officer
mgeremia@vasatherapeutics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/vasa-therapeutics-announces-participation-at-the-36th-annual-oppenheimer-life-sciences-conference-302686822.html
SOURCE Vasa Therapeutics
